Clinical Trial Update: Research Study of ATG and Rituximab in Renal Transplantation [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial investigating ATG and Rituximab in renal transplant recipients was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Recipients

Drugs mentioned

• ATG (anti-thymocyte globulin)
• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Renal Transplant Recipients | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2017-10-04